Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.

The company has partnered to conduct a first-of-its-kind Phase 2 study of AL001 for the treatment of patients with post-traumatic stress disorder (PTSD).

Lithium was the first mood stabilizer approved by the FDA and is still a first-line treatment option for bipolar disorder.

Although lithium does not have an FDA-approved indication for PTSD, case reports suggest that lithium treatment may be useful for treating PTSD patients.

In particular, treatment with low doses (300–600 mg/day) of lithium carbonate has been reported to provide effective treatment in the reduction of inappropriate anger, irritability, anxiety, and insomnia in those patients.

The objective of this novel trial is to assess the comparative increase in lithium levels within the brain and its structures as opposed to a commonly marketed lithium salt among PTSD patients.

Alzamend aims to predict the minimum dose necessary to achieve the equivalent effectiveness and safety of AL001 in contrast to established lithium salts.

Alzamend is optimistic that this study will help meet the regulatory safety standards through the Section 505(b)(2) pathway for FDA approval.

In May, Alzamend Neuro announced its decision to terminate its “at-the-market” equity offering program.

Earlier this month, Alzamend Neuro partnered with Massachusetts General Hospital as its contract research organization to conduct a Phase 2 clinical trial of AL001 for Alzheimer’s.

Price Action: ALZN stock is up 267.7% at $7.50 at last check Monday.

Photo via Shutterstock

Read Next:

• Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy.

Don’t miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you’re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!